What do the trials say — and why did the most famous review get withdrawn?
Zinc's evidence base is dominated by one clinical question — does it shorten colds? — whose literature looks contradictory until you read it as a formulation story. The honest summary: the lozenge evidence is real for the right salts at the right doses taken at the right time (mixed, not miraculous — a day or two of duration reduction); the immune-deficiency correction evidence is solid; the testosterone story is deficiency-correction only; and the copper-paradox harm literature is the safety spine that governs every dosing recommendation on this page.
The cold literature is the field's formulation lesson at grand scale:
Jules Raulin demonstrates that the mold Aspergillus niger cannot grow without zinc — the first essentiality demonstration in any organism.
Todd and colleagues show zinc deficiency produces growth retardation in rats — the animal model established.
Ananda Prasad documents human zinc deficiency in phytate-fed, clay-eating Iranian adolescents — the doctrine of human sufficiency overturned, the field founded.
A 3-year-old's dissolved zinc tablet resolves her cold overnight — the local ionic-zinc mechanism discovered, the cold-lozenge field launched.
The Age-Related Eye Disease Study finds the antioxidant-plus-zinc formula slows macular degeneration progression — zinc's strongest outcome evidence outside deficiency.
Over 100 reports of permanent smell loss from zinc nasal products prompt the FDA warning — the mucosal route's safe/unsafe line drawn.
The Cochrane review finds zinc shortens colds, then is partially withdrawn amid methodological criticism — the evidence-process lesson that outlasts the specific conclusion.
POPULATION · 65 patients, zinc gluconate lozenges vs. placebo, common cold
FINDING · Zinc gluconate lozenges (dissolved in the mouth) significantly shortened cold duration versus placebo — the field's founding trial.
LIMITATION · Small sample, the first of a formulation-dependent literature; the subsequent four decades have refined which salts work and which don't. Eby's accidental observation, formalized.
POPULATION · Zinc-deficient patients (the Iranian/Egyptian cohorts and subsequent trials)
FINDING · Zinc repletion restored growth, pubertal development, immune function, and wound healing in the zinc-deficient — the deficiency-correction evidence base.
LIMITATION · The correction trials demonstrate restoration, not optimization beyond normal — the population-conditional rule this page teaches. The replete majority's non-response is not a null but a boundary.
POPULATION · Zinc-restricted healthy men (dietary restriction study)
FINDING · Dietary zinc restriction lowered testosterone by ~75% in 5 months; zinc repletion restored it — the deficiency-testosterone connection established in controlled conditions.
LIMITATION · A restriction-repletion protocol in a small sample — it demonstrates the deficiency mechanism, not a supplement benefit in the replete. The men's-health marketing borrows this and applies it to the sufficient.
POPULATION · Case series of chronic high-dose zinc users presenting with anemia and/or myelopathy
FINDING · Chronic zinc supplementation (often 50–100+ mg daily from supplements and denture creams) induced copper deficiency with anemia and, in some cases, irreversible neurological damage — the harm that set the 40 mg/day ceiling.
LIMITATION · Case-series literature (the harm presents rarely enough that RCTs are impossible); the mechanism (metallothionein induction blocking copper absorption) is well-established biochemistry. The ceiling is set by this literature.